Amphastar Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Amphastar Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $170.18 million for the year ending 2025.

  • Amphastar Pharmaceuticals, Inc. showed an increase of +12.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 15 years of available data (2011 to 2025), Amphastar Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 216.7%.
  • Historical annual values: Fiscal year 2025: $170.18 million | Fiscal year 2024: $151.61 million | Fiscal year 2023: $144.30 million | Fiscal year 2022: $156.10 million | Fiscal year 2021: $126.35 million | Fiscal year 2020: $92.64 million | Fiscal year 2019: $73.69 million | Fiscal year 2018: $86.34 million | Fiscal year 2017: $65.59 million | Fiscal year 2016: $72.35 million | Fiscal year 2015: $66.07 million | Fiscal year 2014: $67.83 million | Fiscal year 2013: $53.59 million | Fiscal year 2012: $50.21 million | Fiscal year 2011: $53.74 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: